Linezolid for drug-resistant pulmonary tuberculosis

Linezolid was recently re-classified as a Group A drug by the World Health Organization (WHO) for treatment of multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), suggesting that it should be included in the regimen for all patients unless contraindicated...

Celý popis

Podrobná bibliografie

Vydáno v:	Cochrane database of systematic reviews Ročník 3; s. CD012836
Hlavní autoři:	Singh, Bhagteshwar, Cocker, Derek, Ryan, Hannah, Sloan, Derek J
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 20.03.2019
Témata:	Antibiotics, Antitubercular - adverse effects Antibiotics, Antitubercular - therapeutic use Humans Linezolid - adverse effects Linezolid - therapeutic use Non-Randomized Controlled Trials as Topic Randomized Controlled Trials as Topic Treatment Outcome Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - mortality Tuberculosis, Pulmonary - drug therapy Tuberculosis, Pulmonary - mortality Withholding Treatment - statistics & numerical data
ISSN:	1469-493X, 1469-493X
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!